ADA ARIZMENDI: Open Payments
NPI 1043789860 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$734 in 24 payments from 11 companies in 2025. Trend: 2023 $3,755 · 2024 $1,275 · 2025 $734
Food & beverage: $734
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $291 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $237 |
| Janssen Biotech, Inc. | 2 | $44 |
| PFIZER INC. | 1 | $28 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| VIVUS LLC | 1 | $20 |
| Ardelyx, Inc. | 1 | $19 |
| GENZYME CORPORATION | 1 | $18 |
| Braintree Laboratories, Inc. | 1 | $17 |
Products named: ENTYVIO, SKYRIZI, LINZESS, TREMFYA, CREON, VELSIPITY, MAVYRET, XIFAXAN.
Industry payments across FL — which companies pay providers there.
